


We claim:

1. A compound of formula (I):



(I)


5 wherein:

Z_1 is CR_1 or N, Z_2 is CR_2 or N, Z_3 is CR_3 or N, and Z_4 is CR_4 or N, where no more than two of Z_1 , Z_2 , Z_3 and Z_4 are N;

W_1 is O, S, or NR_5 , one of W_2 and W_3 is N or CR_6 , and the other of W_2 and W_3 is CG; W_1 is NG, W_2 is CR_5 or N, and W_3 is CR_6 or N; or W_1 and W_3 are N, and W_2 is NG;

10

G is of formula (II):



(II)

Y is O, S, CHOH, $-NHC(O)-$, $-C(O)NH-$, $-C(O)-$, $-OC(O)-$, $-(O)CO-$, $-NR_7-$, $-CH=N-$, or absent;

15 p is 1, 2, 3, 4 or 5;

Z is CR_8R_9 or absent;

each t is 1, 2, or 3;

each R_1 , R_2 , R_3 , and R_4 , independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} heteroalkyl, C_{1-6} haloalkyl, $-CN$, $-CF_3$, $-OR_{11}$, $-COR_{11}$, $-NO_2$, $-SR_{11}$, $-NHC(O)R_{11}$, $-C(O)NR_{12}R_{13}$, $-NR_{12}R_{13}$, $-NR_{11}C(O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, $-OC(O)R_{11}$, $-O(CH_2)_qNR_{12}R_{13}$, or $-(CH_2)_qNR_{12}R_{13}$, where q is an integer from 2 to 6, or R_1 and R_2 together form $-NH-N=N-$ or R_3 and R_4 together form $-NH-N=N-$;

25 each R_5 , R_6 , and R_7 , independently, is H, C_{1-6} alkyl; formyl; C_{3-6} cycloalkyl; C_{5-6} aryl, optionally substituted with halo or C_{1-6} alkyl; or C_{5-6} heteroaryl, optionally substituted with halo or C_{1-6} alkyl;

each R_8 and R_9 , independently, is H or straight- or branched-chain C_{1-8} alkyl;

R₁₀ is H, straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkylidene, C₁₋₈ alkoxy, C₁₋₈ heteroalkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₁₋₈ hydroxyalkoxy, C₁₋₈ hydroxyalkyl, -SH, C₁₋₈ alkylthio, -O-CH₂-C₅₋₆ aryl, -C(O)-C₅₋₆ aryl substituted with C₁₋₃ alkyl or halo, C₅₋₆ aryl, C₅₋₆ cycloalkyl, C₅₋₆ heteroaryl, C₅₋₆ heterocycloalkyl, -NR₁₂R₁₃, -C(O)NR₁₂R₁₃, -NR₁₁C(O)NR₁₂R₁₃, -CR₁₁R₁₂R₁₃, -OC(O)R₁₁, -(O)(CH₂)_sNR₁₂R₁₃ or -(CH₂)_sNR₁₂R₁₃, s being an integer from 2 to 8;




R_{10'} is H, straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkylidene, C₁₋₈ alkoxy, C₁₋₈ heteroalkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₁₋₈ hydroxyalkoxy, C₁₋₈ hydroxyalkyl, or C₁₋₈ alkylthio;

each R₁₁, independently, is H, straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₂₋₈ heteroalkyl, C₂₋₈ aminoalkyl, C₂₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₂₋₈ hydroxyalkyl, -C(O)-C₅₋₆ aryl substituted with C₁₋₃ alkyl or halo, C₅₋₆ aryl, C₅₋₆ heteroaryl, C₅₋₆ cycloalkyl, C₅₋₆ heterocycloalkyl, -C(O)NR₁₂R₁₃, -CR₅R₁₂R₁₃, -(CH₂)_tNR₁₂R₁₃, t is an integer from 2 to 8; and

each R₁₂ and R₁₃, independently, is H, C₁₋₆ alkyl; C₃₋₆ cycloalkyl; C₅₋₆ aryl, optionally substituted with halo or C₁₋₆ alkyl; or C₅₋₆ heteroaryl, optionally substituted with halo or C₁₋₆ alkyl; or R₁₂ and R₁₃ together form a cyclic structure;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

- 20 2. The compound of claim 1, wherein each t is 2 and R₁₀ is straight- or branched-chain C₂₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkylidene, C₁₋₈ alkoxy, or C₁₋₈ heteroalkyl.
3. The compound of claim 2, wherein R₁₀ is *n*-butyl.
4. The compound of claim 1, wherein Z₁ is CR₁ or N, Z₂ is CR₂, Z₃ is CR₃ or N, and Z₄ is CR₄.
- 25 5. The compound of claim 4, wherein each R₁, R₂, R₃, and R₄, independently, is H, halo, -NO₂, or straight- or branched-chain C₁₋₆ alkyl, or R₁ and R₂ together form -NH-N=N- or R₃ and R₄ together form -NH-N=N-.
6. The compound of claim 2, wherein Y is absent or O, p is 0, 1, 2 or 3, and R₈ and R₉ are H.
- 30 7. The compound of claim 6, wherein Z is absent, Y is absent and p is 3.
8. The compound of claim 7, wherein R₁₀ is *n*-butyl.
9. The compound of claim 2, wherein the compound is of the formula



or

wherein W_1 is O, S, or NR_5 , W_2 is CR_5 or N, and W_3 is CR_5 or N.



10. The compound of claim 9, wherein Z is absent, Y is absent and p is 3.

11. The compound of claim 10, wherein R_{10} is *n*-butyl.

5 12. The compound of claim 9, wherein R_5 is H or C_{1-6} alkyl.

13. The compound of claim 2, wherein the compound is of the formula

or



wherein W_3 is NR_5 , S or O.

14. The compound of claim 13, wherein Z is absent, Y is absent and p is 3.

10 15. The compound of claim 14, wherein R_{10} is *n*-butyl.

16. The compound of claim 13, wherein R_5 is H or C_{1-6} alkyl.

17. The compound of claim 1, wherein the compound is:

2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-benzothiazole;

2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-benzooxazole;

15 4,5-difluoro-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;

6-fluoro-5-nitro-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;

5-tert-butyl-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;

5-chloro-6-methyl-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-

benzoimidazole;

20 4,6-difluoro-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;

2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-imidazo[4,5-*c*]pyridine;

8-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-9*H*-purine;

7-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-3,8-dihydro-

imidazo[4',5':3,4]benzo[1,2-*d*][1,2,3]triazole;

- 2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-3a,4,5,6,7,7a-hexahydro-1*H*-benzoimidazole;
- 1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 5 3-methyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 5-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 3-formyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 7-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indazole;
- 10 3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-benzo[*d*]isoxazole;
- 3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 4-nitro-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 5-nitro-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 4-hydroxy-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 15 2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 4-methyl-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 3-(2-(4-*n*-butylpiperidine)-1-yl-ethyl)-1*H*-indole;
- 3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indazole;
- 3-(2-(4-*n*-butylpiperidine)-ethoxy)-7-methyl-benzo[*d*]isoxazole;
- 20 1-(3-(4-Methylpiperidine)-1-yl-propyl)-1*H*-indazole;
- 1-(3-(4-Pentylpiperidine)-1-yl-propyl)-1*H*-indazole;
- 1-(3-(4-Propylpiperidine)-1-yl-propyl)-1*H*-;
- 1-(3-(4-(3-Methyl-butyl)-piperidine)-1-yl-propyl)-1*H*-indazole
- 1-(3-(4-Pentylidene-piperidine)-1-yl-propyl)-1*H*-indazole;
- 25 1-(3-(4-Propylidene-piperidine)-1-yl-propyl)-1*H*-indazole
- 1-Benzo[*b*]thiophen-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one
- 4-(4-Butylpiperidin-1-yl)-1-(3-methyl-benzofuran-2-yl)-butan-1-one;
- 4-(4-Butylpiperidin-1-yl)-1-(5-fluoro-3-methyl-benzo[*b*]thiophen-2-yl)-butan-1-one;
- 1-one;
- 30 1-Benzofuran-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one;
- 1-(3-Bromo-benzo[*b*]thiophen-2-yl)-4-(4-butylpiperidin-1-yl)-butan-1-one
- 1-(3-Benzo[*b*]thiophen-2-yl-propyl)-4-butylpiperidine;
- 1-(3-Benzofuran-2-yl-propyl)-4-butylpiperidine;
- 4-Butyl-1-[3-(3-methyl-benzofuran-2-yl)-propyl]-piperidine;

4-Butyl-1-[3-(5-fluoro-3-methyl-benzo[*b*]thiophen-2-yl)-propyl]-piperidine;
 2-(3-Iodo-propyl)-benzo[*b*]thiophene;
 1-(3-Benzo[*b*]thiophen-2-yl-propyl)-4-methylpiperidine
 1-(3-Benzo[*b*]thiophen-2-yl-propyl)-4-benzylpiperidine;
 5 1-(3-Benzo[*b*]thiophen-2-yl-propyl)-4-(2-methoxy-phenyl)-piperidine;
 2-(3-Bromopropyl)-2H-benzotriazole;
 2-[3-(4-Butylpiperidin-1-yl)-propyl]-2H-benzotriazole;
 1-(3-Bromopropyl)-1H-benzotriazole;
 1-[3-(4-Butylpiperidin-1-yl)-propyl]-1H-benzotriazole;
 10 1-[3-(4-Butylpiperidin-1-yl)-propyl]-1*H*-indole-3-carbaldehyde;
 {1-[3-(4-Butylpiperidin-1-yl)-propyl]-1H-indol-3-yl}-methanol;
 1-[3-(4-Butylpiperidin-1-yl)-propyl]-2-phenyl-1*H*-benzoimidazole;
 1-[3-(4-Butylpiperidin-1-yl)-propyl]-3-chloro-1*H*-indazole;
 1-[3-(4-Butylpiperidin-1-yl)-propyl]-6-nitro-1*H*-indazole;
 15 Benzo[*d*]isoxazol-3-ol;
 3-(2-Chloroethoxy)-benzo[*d*]isoxazole;
 3-[2-(4-Butylpiperidin-1-yl)-ethoxy]-benzo[*d*]isoxazol;
 3-(1H-Indol-3-yl)-propan-1-ol;
 3-[3-(4-Butyl-piperidin-1-yl)-propyl]- 1*H*-indole hydrochloride;
 20 4-(4-Butylpiperidine-1-yl)-butyric acid methyl ester;
 2-[3-(4-Butylpiperidin-1-yl)-propyl]-1-methyl-1H-benzimidazole;
 1H-Indazole-3-carboxylic acid (2-(4-butylpiperidin)-1-yl-ethyl)-amide;
 1-[3-(4-Butylpiperidin-1-yl)-propyl]-5-nitro-1H-indazole;
 2-[3-(4-butylpiperidin-1-yl)-propyl]-5-nitro-2H-indazole;
 25 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-2-methyl-1*H*-indole;
 1-{1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1H-indol-3-yl}-ethanone;
 {1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1H-indol-3-yl}-acetonitrile;
 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1*H*-indole -3-carbonitrile;
 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-5,6-dimethyl-1*H*-benzoimidazole;
 30 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-5(6)-dimethyl-1*H*-benzoimidazole;
 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-5-methoxy-1*H*-benzoimidazole;
 {1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1H-benzoimidazol-2-yl}-methanol;
 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-2-trifluoromethyl-1*H*-benzoimidazole;
 (2-Trimethylstannanyl-phenyl)-carbamic acid *tert*-butyl ester;


[2-(4-Chloro-butyl)-phenyl]-carbamic acid *tert*-butyl ester;
 {2-[4-(4-Butyl-piperidine-1-yl)-butyryl]-phenyl}-carbamic acid *tert*-butyl
 ester;

- 3-[3-(4-Butyl-piperidine-1-yl)-propyl]-1H-indazole, HCl;
 5 3-[3-(4-Butyl-piperidine-1-yl)-propyl]-5-nitro-1H-indazole;
 3-[3-(4-Butyl-piperidine-1-yl)-propyl]-5,7-dinitro-1H-indazole;
 4-(4-Butyl-piperidin-1-yl)-1-(2-methylsulfanyl-phenyl)-butan-1-one;
 3-[3-(4-Butyl-piperidin-1-yl)-propyl]-benzo[*d*]isothiazole;
 3-[3-(4-Butyl-piperidin-1-yl)-propyl]-5-methoxy-1H-indazole;
 10 3-[3-(4-Butyl-piperidin-1-yl)-propyl]-4-methoxy-1H-indazole
 3-[3-(4-Butyl-piperidin-1-yl)-propyl]-6-methoxy-1H-indazole;
 3-[3-(4-Butyl-piperidin-1-yl)-propyl]-1H-indazole-4-ol (53MF51);
 3-[3-(4-Butyl-piperidin-1-yl)-propyl]-1H-indazole-6-ol (53MF52); or
 3-[3-(4-Butyl-piperidin-1-yl)-propyl]-1H-indazole-5-ol

15

18. A pharmaceutical composition comprising an effective amount of a compound of
 formula (I):

(I)



20


wherein:

Z_1 is CR_1 or N, Z_2 is CR_2 or N, Z_3 is CR_3 or N, and Z_4 is CR_4 or N, where no
 more than two of Z_1 , Z_2 , Z_3 and Z_4 are N;

W_1 is O, S, or NR_5 , one of W_2 and W_3 is N or CR_6 , and the other of W_2 and
 W_3 is CG; W_1 is NG, W_2 is CR_5 or N, and W_3 is CR_6 or N; or W_1 and W_3 are N, and

25

W_2 is NG;




G is of formula (II):

(II)


- Y is O, S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, -(O)CO-, -NR₇-, -CH=N-, or absent;
- p is 1, 2, 3, 4 or 5;
- Z is CR₈R₉ or absent;
- 5 each t is 1, 2, or 3;
- each R₁, R₂, R₃, and R₄, independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ heteroalkyl, C₁₋₆ haloalkyl, -CN, -CF₃, -OR₁₁, -COR₁₁, -NO₂, -SR₁₁, -NHC(O)R₁₁, -C(O)NR₁₂R₁₃, -NR₁₂R₁₃, -NR₁₁C(O)NR₁₂R₁₃, -SO₂NR₁₂R₁₃, -OC(O)R₁₁, -O(CH₂)_qNR₁₂R₁₃, or -
- 10 (CH₂)_qNR₁₂R₁₃, where q is an integer from 2 to 6, or R₁ and R₂ together form -NH-N=N- or R₃ and R₄ together form -NH-N=N-;
- each R₅, R₆, and R₇, independently, is H, C₁₋₆ alkyl; formyl; C₃₋₆ cycloalkyl; C₅₋₆ aryl, optionally substituted with halo or C₁₋₆ alkyl; or C₅₋₆ heteroaryl, optionally substituted with halo or C₁₋₆ alkyl;
- 15 each R₈ and R₉, independently, is H or straight- or branched-chain C₁₋₈ alkyl;
- R₁₀ is straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkylidene, C₁₋₈ alkoxy, C₁₋₈ heteroalkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₁₋₈ hydroxyalkoxy, C₁₋₈ hydroxyalkyl, -SH, C₁₋₈ alkylthio, -O-CH₂-
- 20 C₅₋₆ aryl, -C(O)-C₅₋₆ aryl substituted with C₁₋₃ alkyl or halo, C₅₋₆ aryl, C₅₋₆ cycloalkyl, C₅₋₆ heteroaryl, C₅₋₆ heterocycloalkyl, -NR₁₂R₁₃, -C(O)NR₁₂R₁₃, -NR₁₁C(O)NR₁₂R₁₃, -CR₁₁R₁₂R₁₃, -OC(O)R₁₁, -(O)(CH₂)_sNR₁₂R₁₃ or -(CH₂)_sNR₁₂R₁₃, s being an integer from 2 to 8;
- R₁₀' is H, straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkylidene, C₁₋₈ alkoxy, C₁₋₈ heteroalkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₁₋₈ hydroxyalkoxy, C₁₋₈ hydroxyalkyl, or C₁₋₈ alkylthio;
- 25 each R₁₁, independently, is H, straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₂₋₈ heteroalkyl, C₂₋₈ aminoalkyl, C₂₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₂₋₈ hydroxyalkyl, -C(O)-C₅₋₆ aryl substituted with C₁₋₃ alkyl or halo, C₅₋₆ aryl, C₅₋₆ heteroaryl, C₅₋₆ cycloalkyl, C₅₋₆ heterocycloalkyl, -C(O)NR₁₂R₁₃, -
- 30 CR₅R₁₂R₁₃, -(CH₂)_tNR₁₂R₁₃, t is an integer from 2 to 8; and
- each R₁₂ and R₁₃, independently, is H, C₁₋₆ alkyl; C₃₋₆ cycloalkyl; C₅₋₆ aryl, optionally substituted with halo or C₁₋₆ alkyl; or C₅₋₆ heteroaryl, optionally substituted with halo or C₁₋₆ alkyl; or R₁₂ and R₁₃ together form a cyclic structure;
- or a pharmaceutically acceptable salt, ester or prodrug thereof.

19. The pharmaceutical composition of claim 18, wherein each t is 2 and R_{10} is straight- or branched-chain C_{2-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} alkylidene, C_{1-8} alkoxy, or C_{1-8} heteroalkyl.
20. The pharmaceutical composition of claim 19, wherein R_{10} is n -butyl.
21. The pharmaceutical composition of claim 19, wherein Z_1 is CR_1 or N, Z_2 is CR_2 , Z_3 is CR_3 or N, and Z_4 is CR_4 .
22. The pharmaceutical composition of claim 21, wherein each R_1 , R_2 , R_3 , and R_4 , independently, is H, halo, $-NO_2$, or straight- or branched-chain C_{1-6} alkyl, or R_1 and R_2 together form $-NH-N=N-$ or R_3 and R_4 together form $-NH-N=N-$.
23. The pharmaceutical composition of claim 19, wherein Y is absent or O, p is 0, 1, 2 or 3, and R_8 and R_9 are H.
24. The pharmaceutical composition of claim 23, wherein Z is absent, Y is absent and p is 3.
25. The pharmaceutical composition of claim 24, wherein R_{10} is n -butyl.
26. The pharmaceutical composition of claim 19, wherein the compound is of the formula



wherein W_1 is O, S, or NR_5 , W_2 is CR_5 or N, and W_3 is CR_5 or N.

27. The pharmaceutical composition of claim 26, wherein Z is absent, Y is absent and p is 3.
28. The pharmaceutical composition of claim 27, wherein R_{10} is n -butyl.
29. The pharmaceutical composition of claim 26, wherein R_5 is H or C_{1-6} alkyl.
30. The pharmaceutical composition of claim 19, wherein the compound is of the formula




wherein W₃ is NR₅, S or O.

31. The pharmaceutical composition of claim 30, wherein Z is absent, Y is absent and p is 3.
32. The pharmaceutical composition of claim 31, wherein R₁₀ is *n*-butyl.
- 5 33. The pharmaceutical composition of claim 30, wherein R₅ is H or C₁₋₆ alkyl.
34. The pharmaceutical composition of claim 19, wherein the compound is:
- 2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-benzothiazole;
- 2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-benzooxazole;
- 4,5-difluoro-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;
- 10 6-fluoro-5-nitro-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;
- 5-tert-butyl-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;
- 5-chloro-6-methyl-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;
- 4,6-difluoro-2-(3-(4-*n*-butylpiperidine-1-yl)-propyl)-1*H*-benzoimidazole;
- 15 2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-imidazo[4,5-*c*]pyridine;
- 8-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-9*H*-purine;
- 7-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-3,8-dihydro-imidazo[4',5':3,4]benzo[1,2-*d*][1,2,3]triazole;
- 2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-3*a*,4,5,6,7,7*a*-hexahydro-1*H*-benzoimidazole;
- 20 1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 3-methyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 5-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 25 3-formyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 7-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indazole;
- 3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-benzo[*d*]isoxazole;
- 3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;
- 30 4-nitro-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 5-nitro-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 4-hydroxy-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;
- 4-methyl-2-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;

3-(2-(4-*n*-butylpiperidine)-1-yl-ethyl)-1*H*-indole; or

3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indazole.

35. A method of increasing an activity of a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of formula (I):




(I)

wherein:

- Z_1 is CR_1 or N, Z_2 is CR_2 or N, Z_3 is CR_3 or N, and Z_4 is CR_4 or N, where no more than two of Z_1 , Z_2 , Z_3 and Z_4 are N;

W_1 is O, S, or NR_5 , one of W_2 and W_3 is N or CR_6 , and the other of W_2 and W_3 is CG; W_1 is NG, W_2 is CR_5 or N, and W_3 is CR_6 or N; or W_1 and W_3 are N, and W_2 is NG;

G is of formula (II):



(II)

Y is O, S, CHOH, $-NHC(O)-$, $-C(O)NH-$, $-C(O)-$, $-OC(O)-$, $-(O)CO-$, $-NR_7-$, $-CH=N-$, or absent;

p is 1, 2, 3, 4 or 5;

Z is CR_8R_9 or absent;

each t is 1, 2, or 3;

- each R_1 , R_2 , R_3 , and R_4 , independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} heteroalkyl, C_{1-6} haloalkyl, $-CN$, $-CF_3$, $-OR_{11}$, $-COR_{11}$, $-NO_2$, $-SR_{11}$, $-NHC(O)R_{11}$, $-C(O)NR_{12}R_{13}$, $-NR_{12}R_{13}$, $-NR_{11}C(O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, $-OC(O)R_{11}$, $-O(CH_2)_qNR_{12}R_{13}$, or $-(CH_2)_qNR_{12}R_{13}$, where q is an integer from 2 to 6, or R_1 and R_2 together form $-NH-N=N-$ or R_3 and R_4 together form $-NH-N=N-$;

each R₅, R₆, and R₇, independently, is H, C₁₋₆ alkyl; formyl; C₃₋₆ cycloalkyl; C₅₋₆ aryl, optionally substituted with halo or C₁₋₆ alkyl; or C₅₋₆ heteroaryl, optionally substituted with halo or C₁₋₆ alkyl;

each R₈ and R₉, independently, is H or straight- or branched-chain C₁₋₈ alkyl;

- 5 R₁₀ is straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkylidene, C₁₋₈ alkoxy, C₁₋₈ heteroalkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₁₋₈ hydroxyalkoxy, C₁₋₈ hydroxyalkyl, -SH, C₁₋₈ alkylthio, -O-CH₂-C₅₋₆ aryl, -C(O)-C₅₋₆ aryl substituted with C₁₋₃ alkyl or halo, C₅₋₆ aryl, C₅₋₆ cycloalkyl, C₅₋₆ heteroaryl, C₅₋₆ heterocycloalkyl, -NR₁₂R₁₃, -C(O)NR₁₂R₁₃, -NR₁₁C(O)NR₁₂R₁₃, -
10 CR₁₁R₁₂R₁₃, -OC(O)R₁₁, -(O)(CH₂)_sNR₁₂R₁₃ or -(CH₂)_sNR₁₂R₁₃, s being an integer from 2 to 8;

R_{10'} is H, straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₈ alkylidene, C₁₋₈ alkoxy, C₁₋₈ heteroalkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₁₋₈ hydroxyalkoxy, C₁₋₈ hydroxyalkyl, or C₁₋₈ alkylthio;

- 15 each R₁₁, independently, is H, straight- or branched-chain C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₂₋₈ heteroalkyl, C₂₋₈ aminoalkyl, C₂₋₈ haloalkyl, C₁₋₈ alkoxycarbonyl, C₂₋₈ hydroxyalkyl, -C(O)-C₅₋₆ aryl substituted with C₁₋₃ alkyl or halo, C₅₋₆ aryl, C₅₋₆ heteroaryl, C₅₋₆ cycloalkyl, C₅₋₆ heterocycloalkyl, -C(O)NR₁₂R₁₃, -
CR₅R₁₂R₁₃, -(CH₂)_tNR₁₂R₁₃, t is an integer from 2 to 8; and

- 20 each R₁₂ and R₁₃, independently, is H, C₁₋₆ alkyl; C₃₋₆ cycloalkyl; C₅₋₆ aryl, optionally substituted with halo or C₁₋₆ alkyl; or C₅₋₆ heteroaryl, optionally substituted with halo or C₁₋₆ alkyl; or R₁₂ and R₁₃ together form a cyclic structure;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

36. The method of claim 35 wherein the cholinergic receptor is a muscarinic receptor.

- 25 37. The method of claim 36 wherein the muscarinic receptor is of the m1 muscarinic receptor subtype.

38. The method of claim 36 wherein the muscarinic receptor is of the m4 muscarinic receptor subtype.

39. The method of claim 36 wherein the muscarinic receptor is in the central nervous
30 system.

40. The method of claim 36 wherein the muscarinic receptor is in the peripheral nervous system.

41. The method of claim 36 wherein the muscarinic receptor is in the gastrointestinal system, heart, endocrine glands, or lungs.

42. The method of claim 36 wherein the muscarinic receptor is truncated, mutated, or modified.
43. The method of claim 35 wherein the activity is a signaling activity of a cholinergic receptor.
- 5 44. The method of claim 35 wherein the activity is associated with muscarinic receptor activation.
45. The method of claim 35 wherein the compound is a cholinergic agonist.
46. The method of claim 35 wherein the compound is selective for the m1, or m4 muscarinic receptor subtype, or both the m1 and m4 muscarinic receptor subtypes.
- 10 47. A method of activating a cholinergic receptor comprising contacting the cholinergic receptor or a system containing the cholinergic receptor with an effective amount of at least one compound of claim 1.
48. The method of claim 47 wherein the compound is a cholinergic agonist.
49. The method of claim 47 wherein the compound is selective for the m1, m4, or
15 both the m1 and m4 muscarinic receptor subtype.
50. The method of claim 47 wherein the cholinergic receptor is a muscarinic receptor.
51. The method of claim 47 wherein the muscarinic receptor is the m1 or m4 muscarinic receptor subtype.
52. The method of claim 47 wherein the muscarinic receptor is in the central nervous
20 system.
53. The method of claim 47 wherein the muscarinic receptor is in the peripheral nervous system.
54. The method of claim 47 wherein the muscarinic receptor is in the gastrointestinal system, heart, endocrine glands, or lungs.
- 25 55. The method of claim 47 wherein the muscarinic receptor is truncated, mutated, or modified.
56. A method of treating a disease condition associated with a cholinergic receptor comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1.
- 30 57. The method of claim 56 wherein the disease condition is selected from the group consisting of cognitive impairment, forgetfulness, confusion, memory loss, attentional deficits, deficits in visual perception, depression, pain, sleep disorders, psychosis, hallucinations, aggressiveness, paranoia, and increased intraocular pressure.

58. The method of claim 56 wherein the disease condition is selected from the group consisting of neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Down Syndrome, Pick disease, dementia, clinical depression, age-related cognitive decline, attention-deficit disorder, sudden infant death syndrome, and glaucoma.
59. The method of claim 56 wherein the disease condition is associated with a cholinergic receptor dysfunction.
60. The method of claim 56 wherein the disease condition is associated with decreased activity of a cholinergic receptor.
61. The method of claim 56 wherein the disease condition is associated with loss of cholinergic receptors.
62. The method of claim 56 wherein the cholinergic receptor is a muscarinic receptor
63. The method of claim 62 wherein the muscarinic receptor is the m1 or m4 muscarinic receptor subtype.
64. The method of claim 62 wherein the muscarinic receptor is in the central nervous system.
65. The method of claim 62 wherein the muscarinic receptor is in the peripheral nervous system.
66. The method of claim 62 wherein the muscarinic receptor is in gastrointestinal system, heart, endocrine glands, or lungs.
67. The method of claim 62 wherein the muscarinic receptor is truncated, mutated, or modified.
68. A method of treating a disease condition associated with reduced levels of acetylcholine comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1.
69. A method of treating Alzheimer's Disease comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1.
70. A method of treating cognitive impairment comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1.
71. A method of treating glaucoma comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1.

72. A method of treating pain comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1.
73. A method of treating schizophrenia comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1
- 5 74. A method for identifying a genetic polymorphism predisposing a subject to being responsive to amount of at least one compound of claim 1, comprising:
administering to a subject an therapeutically effective amount of the compound;
measuring the response of said subject to said compound, thereby identifying a
10 responsive subject having an ameliorated disease condition associated with a cholinergic receptor; and
identifying a genetic polymorphism in the responsive subject, wherein the genetic polymorphism predisposes a subject to being responsive to the compound.
- 15 75. The method of claim 74 wherein the ameliorated disease condition is associated with the m1 or m4 muscarinic receptor subtype.
- 20 76. A method for identifying a subject suitable for treatment with at least one compound of claim 1, comprising detecting the presence of a polymorphism in a subject wherein the polymorphism predisposes the subject to being responsive to said compound, and wherein the presence of the polymorphism indicates that the subject is suitable for treatment with said compound of claim 1.